Skip to content
Menu

CSX Corporation CSX

Full chart Compare
Set alert

Price alert · CSX

All alert types
49.10 USD -0.88 (-1.76%)

Regular-session close

49.10 0.00 0.00%

After hours · Nov 20, 5:25 PM ET

48.99 Day range 50.45
33.68 52-week range 53.23
YTD
+35.45%
1 year
+45.78%

Fundamental scorecard

15 of 25 checks passed on CSX’s reported financials

ValueGrowthProfitabilityHealthDividend

15of 25 checks passed

  • Value 0 of 5
  • Growth 5 of 5
  • Profitability 4 of 5
  • Financial health 2 of 5
  • Dividend 4 of 5

Statements to Sep 30, 2026.

Value 0 of 5

  • Failed:P/E below its own 5-year median P/E 25.3 against a 5-year median of 18.7.
  • Failed:P/E under 20 P/E 25.3: an earnings yield of 4.0%.
  • Failed:Price to sales below its own 5-year median Price to sales 6.1 against a 5-year median of 4.7.
  • Failed:Price to book below its own 5-year median Price to book 6.3 against a 5-year median of 5.2.
  • Failed:Free cash flow yield above 4% Free cash flow of 3.37B is 3.7% of the market value.

Growth 5 of 5

  • Passed:Revenue grew over the last year Revenue of 14.9B is +5.8% on the 12 months before.
  • Passed:Revenue grew more than 5% a year over five years +5.9% a year from FY 2020 to FY 2025.
  • Passed:Earnings per share grew over the last year EPS 1.92 against 1.54 in the 12 months before.
  • Passed:Earnings per share grew more than 5% a year over five years +5.1% a year from FY 2020 to FY 2025.
  • Passed:Analysts expect higher earnings per share over the next year The average forward estimate is +22.1% on the last 12 months.

Profitability 4 of 5

  • Passed:Profitable over the last year Net income of 3.58B over the last 12 months.
  • Passed:Profitable in each of the last five fiscal years A profit in 5 of the last 5 fiscal years.
  • Passed:Return on equity above 15% Return on equity of 26.4%.
  • Failed:Net margin above its 5-year average Net margin of 24.0% against a 5-year average of 25.5%.
  • Passed:Free cash flow is at least 80% of net income Free cash flow of 3.37B is 94.1% of net income.

Financial health 2 of 5

  • Failed:Short-term assets cover short-term liabilities Short-term assets of 3.63B against short-term liabilities of 4.31B.
  • Failed:Short-term assets cover long-term liabilities Short-term assets of 3.63B against long-term liabilities of 26.5B.
  • Failed:Net debt under 40% of equity Net debt of 17.7B is 123.0% of equity.
  • Passed:Operating cash flow covers at least 20% of debt Operating cash flow of 5.60B is 29.0% of debt.
  • Passed:Operating profit covers interest at least 3 times Operating profit is 6.6 times the interest expense.

Dividend 4 of 5

  • Passed:Pays a dividend 1.02B paid over the last 12 months.
  • Failed:Yield above 1.5% A yield of 1.1% at the current market value.
  • Passed:Pays out under 75% of profit 28.5% of net income is paid out.
  • Passed:Covered by free cash flow 30.3% of free cash flow is paid out.
  • Passed:Not cut in the last five fiscal years The total paid did not fall in any of the last five fiscal years.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What CSX owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 45.2B of assets

Debt, equity and cash by year

Now: 17.7B of debt after cash

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

2.84 Grey zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

8 / 9 Strong

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

B3 / 5 overall

  • DCF 2
  • Return on Equity 5
  • Return on Assets 5
  • Debt / Equity 1
  • P/E 2
  • P/B 1

Valuation

P/E 23.5×
P/S 4.8×
P/B 5.1×
P/FCF 39.5×
EV/EBITDA 13.8×
EV/Sales 6.1×
FCF Yield 2.5%

Profitability

Gross Margin 33.2%
Operating Margin 32.1%
Net Margin 20.5%
ROE 22.0%
ROIC 8.4%
ROA 6.6%

Growth (YoY)

Revenue -3.1%
Operating Income -15.7%
EPS (diluted) -14.0%
Free Cash Flow -37.0%

Financial Health

Current Ratio 0.8×
Quick Ratio 0.7×
Debt / Equity 1.5×
Net Debt / EBITDA 3.0×
Interest Coverage 5.4×

Dividends

Dividend Yield 1.4%
Payout Ratio 33.6%

Annual · latest fiscal year ends 2025-12-31